Protalix Biotherapeutics Inc Revenue Growth Rates (PLX), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Protalix Biotherapeutics inc   (NYSEAMER: PLX)
 

PLX's Revenue Growth by Quarter and Year

Protalix Biotherapeutics Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/PLX/growth
https://api.csimarket.com/api/v1/companies/PLX/fundamentals
https://api.csimarket.com/api/v1/companies/PLX/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
PLX Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 21.93
2nd Quarter June 19.90
1st Quarter March 33.75
FY 75.58

PLXs Annual Revenue
Protalix Biotherapeutics Inc 's Revenue in the fiscal year 2025 $ 52.74 millions
Protalix Biotherapeutics Inc 's Revenue in the fiscal year 2024 $ 53.40 millions
Protalix Biotherapeutics Inc 's Revenue in the fiscal year 2023 $ 65.49 millions
Protalix Biotherapeutics Inc 's Revenue in the fiscal year 2022 $ 47.64 millions
Protalix Biotherapeutics Inc 's Revenue in the fiscal year 2021 $ 38.35 millions




PLX Revenue third quarter 2026 Y/Y Growth Comment
Protalix Biotherapeutics inc reported Revenue improvement of 22.83% year on year in the third quarter 2026, to $ 21.93 millions, this is lower than Protalix Biotherapeutics Inc 's recent average Revenue rise of 72.57%.

Looking into third quarter 2026 results within Biotechnology & Pharmaceuticals industry 36 other companies have achieved higher Revenue growth. While Protalix Biotherapeutics Inc ' s Revenue rise of 22.83% ranks overall at the positon no. 2200 in the third quarter 2026.


PLX Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 22.83 %
2nd Quarter June 27.08 %
1st Quarter March 233.83 %
FY   -

Financial Statements
Protalix Biotherapeutics Inc 's third quarter 2026 Revenue $ 21.93 millions PLX's Income Statement
Protalix Biotherapeutics Inc 's third quarter 2025 Revenue $ 17.85 millions Quarterly PLX's Income Statement


PLX Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 10.18 %
2nd Quarter June -41.04 %
1st Quarter March 270.07 %
FY (Year on Year)   -


Back to PLX Growth rate Comparisons >> Back to PLX Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #37
Healthcare Sector #324
Overall #2200

Revenue Y/Y Growth Statistics
High Average Low
1652.53 % 72.57 % -115.71 %
(Mar 31 2017)   (Sep 30 2016)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #37
Healthcare Sector #324
Overall #2200
Revenue Y/Y Growth Statistics
High Average Low
1652.53 % 72.57 % -115.71 %
(Mar 31 2017)   (Sep 30 2016)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Protalix Biotherapeutics Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
576.33 % 46.68 % -100 %
(Jun 30 2012)  


PLX's III. Quarter Q/Q Revenue Comment
Protalix Biotherapeutics inc achieved in the III. Quarter 2026 below company average Revenue rise of 10.18% quarter on quarter, to $ 21.93 millions.

Within Biotechnology & Pharmaceuticals industry 50 other companies have achieved higher Revenue quarter on quarter growth. While Protalix Biotherapeutics Inc 's Revenue growth quarter on quarter, overall rank is 3603.


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #51
Healthcare Sector #512
Overall #3603
Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #51
Healthcare Sector #512
Overall #3603
Revenue Q/Q Growth Statistics
High Average Low
576.33 % 46.68 % -100 %
(Jun 30 2012)  


PLX's III. Quarter Q/Q Revenue Comment
Protalix Biotherapeutics inc achieved in the III. Quarter 2026 below company average Revenue rise of 10.18% quarter on quarter, to $ 21.93 millions.

Within Biotechnology & Pharmaceuticals industry 50 other companies have achieved higher Revenue quarter on quarter growth. While Protalix Biotherapeutics Inc 's Revenue growth quarter on quarter, overall rank is 3603.


Protalix Biotherapeutics Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2026)		 12 Months Ending (Jun 30 2026) 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025)
Cumulative Revenue 12 Months Ending $ 84.69
Y / Y Revenue Growth (TTM) 36.96 %
Year on Year Revenue Growth Overall Ranking # 261
Seqeuential Revenue Change (TTM) 5.05 %
Seq. Revenue Growth (TTM) Overall Ranking # 2200


Cumulative Revenue growth Comment
Although Protalix Biotherapeutics Inc 's Annual Revenue growth year on year were below company's average 72.57% , Revenue announced in the Sep 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 36.96% year on year, from 30.14% in Jun 30 2026.

In the Healthcare sector 72 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 261, from total ranking in previous quarter at 2138.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 37
Healthcare Sector # 73
Overall # 261

Revenue TTM Y/Y Growth Statistics
High Average Low
1652.53 %
 72.57 %
-115.71 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 37
Sector # 324
S&P 500 # 2200
Cumulative Revenue growth Comment
Although Protalix Biotherapeutics Inc 's Annual Revenue growth year on year were below company's average 72.57% , Revenue announced in the Sep 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 36.96% year on year, from 30.14% in Jun 30 2026.

In the Healthcare sector 72 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 261, from total ranking in previous quarter at 2138.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 37
Healthcare Sector # 73
Overall # 261

Revenue TTM Y/Y Growth Statistics
High Average Low
1652.53 %
72.57 %
-115.71 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 37
Sector # 324
S&P 500 # 2200




Other Revenue Growth
Biotechnology & Pharmaceuticals Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
PLX's Revenue Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue rise for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Mirum Pharmaceuticals Inc 39.63%$ 39.629 millions
Caredx Inc 39.29%$ 39.285 millions
Halozyme Therapeutics Inc 39.15%$ 39.154 millions
Eli Lilly And Company38.61%$ 38.613 millions
Sbc Medical Group Holdings Incorporated37.48%$ 37.478 millions
Myomo Inc 37.42%$ 37.416 millions
Editas Medicine Inc 37.41%$ 37.412 millions
Beyond Air Inc 36.55%$ 36.545 millions
Clearpoint Neuro Inc 36.27%$ 36.271 millions
Regeneron Pharmaceuticals Inc 36.27%$ 36.265 millions
Travere Therapeutics Inc 36.22%$ 36.215 millions
Omada Health Inc 36.13%$ 36.133 millions
Guardant Health Inc 36.12%$ 36.116 millions
Natera Inc 34.08%$ 34.077 millions
Establishment Labs Holdings Inc 34.08%$ 34.075 millions
Beone Medicines Ltd 33.86%$ 33.861 millions
Ceribell Inc 33.72%$ 33.721 millions
Zomedica Corp 33.12%$ 33.123 millions
Intuitive Surgical Inc 32.71%$ 32.714 millions
Adc Therapeutics Sa32.20%$ 32.197 millions
Biomarin Pharmaceutical Inc32.02%$ 32.019 millions
The Pennant Group Inc 31.96%$ 31.965 millions
Beta Bionics Inc 30.92%$ 30.923 millions
Cadre Holdings inc 30.36%$ 30.362 millions
Krystal Biotech Inc 30.21%$ 30.206 millions
Sight Sciences Inc 29.83%$ 29.828 millions
Biofrontera Inc 29.79%$ 29.794 millions
Ge Healthcare Technologies Inc 29.41%$ 29.413 millions
Moderna Inc 29.23%$ 29.232 millions
Sonoma Pharmaceuticals Inc 28.02%$ 28.016 millions


About Protalix Biotherapeutics Inc Revenue Growth Rates (PLX), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Protalix Biotherapeutics Inc (CIK 1006281).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001104659-26-124771
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Protalix Biotherapeutics Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.